Gut microbiota interventions may improve glucose and cardiometabolic markers in type 2 diabetes
Last updated May 26, 2026
Key finding
This systematic review found that microbiota-directed strategies, including probiotics, personalized nutrition, and diet changes, were often linked with better glycemic and cardiometabolic markers, but study methods and results varied across trials.
This paper reviewed 10 intervention studies on gut microbiota-directed approaches in type 2 diabetes and related metabolic risk groups. Many studies reported better HbA1c, insulin sensitivity, lipids, or inflammation, but effects were not fully consistent. Because trials differed in design, duration, and populations, the overall evidence is promising but still uncertain.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Low
Study type
Systematic Review
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This systematic review found that microbiota-directed strategies, including probiotics, personalized nutrition, and diet changes, were often linked with better glycemic and cardiometabolic markers, but study methods and results varied across trials.
Published in
Journal Reference
Publication details and source links for this paper.
Ur Rehman M, Saeed H, Omer O, Tashfeen S. Gut Microbiota-Directed Interventions in Type 2 Diabetes: A Systematic Review of Clinical Outcomes and Complication Risk. Cureus. 2025;17(10):e95045. doi:10.7759/cureus.95045
Main Effects
HbA1c ↓ in several included intervention trials
Insulin resistance ↓ in multiple microbiota-targeted strategies
Cardiometabolic markers (lipids, blood pressure, CRP) often improved
Evidence Suggest
- Several trials reported better glycemic and insulin sensitivity markers after microbiota-directed interventions.
- Some studies found stronger effects with combined or personalized strategies than with standard comparators.
- Outcome variability across studies limits confidence in a single effect size.
Who this applies to
Adults with type 2 diabetes
Keep in Mind
This is a review-level synthesis, not one primary intervention trial.
Between the Lines
- No pooled meta-analysis due to heterogeneity
- Many included trials were short-term
- Several studies had small sample sizes
- Interventions and measured outcomes varied substantially
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.